Holen Sie sich die Stockscreener-App
98.77
0.30%
0.15
Handel nachbörslich:
98.90
0.13
+0.13%
Schlusskurs vom Vortag:
$98.62
Offen:
$98.84
24-Stunden-Volumen:
500.17K
Relative Volume:
0.51
Marktkapitalisierung:
$6.03B
Einnahmen:
$521.31M
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-206.59
EPS:
-0.4781
Netto-Cashflow:
$54.87M
1W Leistung:
+3.41%
1M Leistung:
+8.12%
6M Leistung:
+35.26%
1J Leistung:
+124.81%
1-Tages-Spanne:
$95.62
$99.99
1-Wochen-Bereich:
$95.62
$101.96
52-Wochen-Spanne:
$43.30
$114.99
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
98.96 | 6.01B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-09-24 | Eingeleitet | TD Cowen | Buy |
| 2025-08-11 | Fortgesetzt | Stifel | Buy |
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
US604749AC5 Bond Analysis — Key Metrics - TradingView
US604749AC5 Bond Price and Chart — FWB:US604749AC5 - TradingView
Mirum’s US$600 Million Zero-Coupon Convertible Note Issue Might Change The Case For Investing In Mirum Pharmaceuticals (MIRM) - Yahoo Finance
Behavioral Patterns of MIRM and Institutional Flows - Stock Traders Daily
Mirum Pharmaceuticals, Inc.common stock (NQ: MIRM - The Chronicle-Journal
MIRM Stock Price, Quote & Chart | MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) - ChartMill
Mirum Pharmaceuticals Set to Present Key Data at International L - GuruFocus
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026 - Business Wire
Mirum Pharmaceuticals Issues $690 Million Convertible Senior Notes - TipRanks
MIRM: Clinical and commercial catalysts drive growth, with major pipeline and BD milestones ahead - TradingView
Mirum Pharma: A rare disease growth story to watch - MSN
Mirum Pharma: A Rare Disease Growth Story to Watch - sharewise.com
Wolfe Research initiates coverage of Mirum Pharmaceuticals (MIRM) with outperform recommendation - MSN
Mirum Pharmaceuticals director Saira Ramasastry sells $218,940 stock By Investing.com - Investing.com Nigeria
This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Wolfe Research initiates Mirum stock with outperform rating By Investing.com - Investing.com Canada
Mirum Pharmaceuticals director Saira Ramasastry sells $218,940 stock - Investing.com UK
[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Mirum Pharmaceuticals (NASDAQ: MIRM) sells $600M 2032 converts, to refinance 2029 notes - Stock Titan
Mirum Pharmaceuticals (MIRM) price target increased by 16.75% to 149.29 - MSN
Mirum Pharmaceuticals prices $600M senior notes - MSN
2,000-share sale via option exercise — MIRM (NASDAQ: MIRM) Form 144 - Stock Titan
Mirum's Q1 earnings & revenues beat estimates, 2026 view raised - MSN
Mirum Pharmaceuticals (MIRM) moves 5.1% higher: Will this strength last? - MSN
Latham & Watkins Advises on Mirum Pharmaceuticals’ US$600 Million Convertible Senior Notes Offering - Latham & Watkins LLP
Mirum Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
(MIRM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Mirum Pharmaceuticals stock hits all-time high at 112.47 USD By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals stock (US60471A1034): Hits all-time high amid $600M debt deal - AD HOC NEWS
Mirum Pharmaceuticals stock hits all-time high at 112.47 USD - Investing.com
Mirum Pharmaceuticals Prices $600 Million Private Debt Offering - Moomoo
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes - BioSpace
Mirum plans $600 million convertible notes offering due 2032 By Investing.com - Investing.com South Africa
Mirum prices $600m convertible notes offering due 2032 By Investing.com - Investing.com South Africa
Mirum prices $600m convertible notes offering due 2032 - Investing.com
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering - TradingView
Mirum raises $600M in 0% convertible notes, starts 2029 debt swap - Stock Titan
Mirum pharmaceuticals announces proposed convertible senior notes offering - marketscreener.com
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering - TradingView
Mirum Pharmaceuticals shares fall 2% after announcing $600 million bond offering - Investing.com Canada
Mirum plans $600 million convertible notes offering due 2032 - Investing.com
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mirum Pharmaceuticals Inc-Aktie (MIRM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ramasastry Saira | Director |
May 15 '26 |
Sale |
109.47 |
2,000 |
218,940 |
0 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):